Get the Stockscreener App
6.756
1.65%
0.106
Evolus Inc stock is traded at $6.756, with a volume of 165.01K.
It is up +1.65% in the last 24 hours and up +3.68% over the past month.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.
See More
Previous Close:
$6.65
Open:
$6.71
24h Volume:
165.01K
Relative Volume:
0.14
Market Cap:
$437.53M
Revenue:
$202.09M
Net Income/Loss:
$-61.69M
P/E Ratio:
-6.2556
EPS:
-1.08
Net Cash Flow:
$-35.64M
1W Performance:
-2.03%
1M Performance:
+3.68%
6M Performance:
-26.60%
1Y Performance:
-39.15%
1-Day Range:
$6.58
$6.76
1-Week Range:
$6.565
$6.93
52-Week Range:
$5.71
$17.12
Evolus Inc Stock (EOLS) Company Profile
Name
Evolus Inc
Sector
Phone
(949) 284-4555
Address
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Compare EOLS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
6.75 | 431.05M | 202.09M | -61.69M | -35.64M | -1.08 |
|
ZTS
Zoetis Inc
|
125.41 | 55.45B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.62 | 49.25B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.02 | 45.02B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.64 | 35.81B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
490.48 | 20.98B | 3.08B | 1.24B | 1.07B | 25.61 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Downgrade | Needham | Buy → Hold |
| Apr-17-25 | Initiated | BTIG Research | Buy |
| Jan-29-24 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-23-22 | Initiated | Needham | Buy |
| May-12-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| May-06-21 | Upgrade | Mizuho | Neutral → Buy |
| Apr-08-21 | Reiterated | H.C. Wainwright | Buy |
| Feb-24-21 | Downgrade | Truist | Buy → Hold |
| Jul-07-20 | Downgrade | Mizuho | Buy → Neutral |
| Feb-06-20 | Resumed | Mizuho | Buy |
| Nov-26-19 | Initiated | SVB Leerink | Outperform |
| Sep-05-19 | Resumed | Mizuho | Buy |
| Jun-28-19 | Initiated | Wells Fargo | Market Perform |
| Jun-11-19 | Initiated | Barclays | Underweight |
| Mar-20-19 | Initiated | SunTrust | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Jan-29-19 | Initiated | Stifel | Buy |
View All
Evolus Inc Stock (EOLS) Latest News
Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR) and Evolus (EOLS) - The Globe and Mail
Discipline and Rules-Based Execution in EOLS Response - Stock Traders Daily
Avelar Rui, Evolus officer, sells $16k in EOLS stock By Investing.com - Investing.com Nigeria
Evolus CEO Moatazedi sells $75k in shares By Investing.com - Investing.com South Africa
Avelar Rui, Evolus officer, sells $16k in EOLS stock - Investing.com
Insider Selling: Evolus (NASDAQ:EOLS) Insider Sells 10,539 Shares of Stock - MarketBeat
Rui Avelar Sells 2,261 Shares of Evolus (NASDAQ:EOLS) Stock - MarketBeat
Evolus CEO Moatazedi sells $75k in shares - Investing.com India
ANI Stock Is Up 49% This Past Year, Revenue Is Surging, and One Fund Still Walked Away - The Motley Fool
Evolus, Inc. $EOLS Shares Acquired by Rice Hall James & Associates LLC - MarketBeat
Big Picture: Does Evolus Inc stock trade at a discount to peersPortfolio Update Summary & AI Powered Buy and Sell Recommendations - moha.gov.vn
Evolus' (EOLS) "Hold" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Needham Reiterates Evolus (EOLS) Hold Recommendation - Nasdaq
Needham Reiterates Hold Rating for Evolus (EOLS) | EOLS Stock Ne - GuruFocus
Mizuho cuts Evolus (EOLS) estimates for Jeuveau/Evolysse on waning consumer sentiment and inflationary pressure on elective aesthetics - MSN
Net current asset value per share of Evolus, Inc. – BER:EVL - TradingView — Track All Markets
Trading the Move, Not the Narrative: (EOLS) Edition - Stock Traders Daily
EV Market: Why Evolus Inc. stock is a must watch in 2025Earnings Growth Summary & Consistent Return Investment Signals - Улправда
Midday Stock Roundup: Rivian Stock Continues to Climb - Orange County Business Journal
Will Evolus Inc. (EVL) stock benefit from sector leadershipInflation Watch & Risk Controlled Stock Alerts - ulpravda.ru
Why Evolus Inc. stock is rated strong buyTrade Risk Summary & Consistent Profit Trading Strategies - DonanımHaber
Will Evolus Inc. stock continue dividend increasesJuly 2025 Spike Watch & Capital Efficient Trade Techniques - DonanımHaber
Why Evolus Inc. stock is a must watch in 2025Insider Selling & Precise Trade Entry Recommendations - Улправда
Can Evolus Inc. stock deliver strong Q4 earningsJuly 2025 Big Picture & AI Powered Buy and Sell Recommendations - Улправда
Can Evolus Inc. stock beat market expectations this quarterGlobal Markets & Daily Chart Pattern Signals - Улправда
Evolus: A Difficult 2025 Means I'm Downgrading Stock To 'Hold' For 2026 (NASDAQ:EOLS) - Seeking Alpha
Evolus, Inc. (NASDAQ:EOLS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Mizuho Cuts Evolus (EOLS) Estimates for Jeuveau/Evolysse on Waning Consumer Sentiment and Inflationary Pressure on Elective Aesthetics - Insider Monkey
20 Stocks That Will Double in 2026 - Insider Monkey
2,435,550 Shares in Evolus, Inc. $EOLS Bought by Frazier Life Sciences Management L.P. - MarketBeat
Midday Stock Roundup: Rivian Rises on Chip, Models - Orange County Business Journal
Frontier Capital Management Co. LLC Buys 457,533 Shares of Evolus, Inc. $EOLS - MarketBeat
Evolus, Inc. Earnings Call Highlights Growth and Resilience - MSN
Jump Financial LLC Grows Stock Position in Evolus, Inc. $EOLS - MarketBeat
Mizuho reaffirms Evolus stock rating at Outperform amid early signs of market stabilization - Investing.com Canada
Evolus Navigates a Path to Profitability Amidst Quarterly Challenges - AD HOC NEWS
(EOLS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Evolus price target lowered to $19 from $20 at Mizuho - MSN
Stonepine Capital Management LLC Has $8.44 Million Holdings in Evolus, Inc. $EOLS - MarketBeat
How Evolus Inc. (EVL) stock compares with tech leadersWeekly Earnings Recap & Technical Entry and Exit Alerts - Newser
Mizuho lowers Evolus stock price target on consumer sentiment concerns By Investing.com - Investing.com Canada
Why Evolus Inc. stock attracts global investorsJuly 2025 Volume & Community Consensus Picks - Newser
Mizuho lowers Evolus stock price target on consumer sentiment concerns - Investing.com India
Is Evolus Inc. stock a defensive play in 2025July 2025 Recap & Technical Pattern Based Buy Signals - Newser
How Evolus Inc. (EVL) stock behaves in tightening cyclesJuly 2025 Closing Moves & Stepwise Entry and Exit Trade Signals - Newser
How cyclical is Evolus Inc. (EVL) stock compared to rivalsEarnings Beat & Free Low Drawdown Momentum Trade Ideas - Newser
How Evolus Inc. (EVL) stock reacts to stronger dollarQuarterly Market Review & Verified Entry Point Signals - Newser
Evolus Inc Stock (EOLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.43%
2.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):